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Abstract
Dominant mutations in the valosin containing protein (VCP) gene cause inclusion body myopathy associated with Paget’s
disease of bone and frontotemporal dementia (IBMPFD). We have generated a knock-in mouse model with the common
R155H mutation. Mice demonstrate progressive muscle weakness starting approximately at the age of 6 months. Histology
of mutant muscle showed progressive vacuolization of myofibrils and centrally located nuclei, and immunostaining shows
progressive cytoplasmic accumulation of TDP-43 and ubiquitin-positive inclusion bodies in quadriceps myofibrils and brain.
Increased LC3-II staining of muscle sections representing increased number of autophagosomes suggested impaired
autophagy. Increased apoptosis was demonstrated by elevated caspase-3 activity and increased TUNEL-positive nuclei. X-
ray microtomography (uCT) images show radiolucency of distal femurs and proximal tibiae in knock-in mice and uCT
morphometrics shows decreased trabecular pattern and increased cortical wall thickness. Bone histology and bone marrow
derived macrophage cultures in these mice revealed increased osteoclastogenesis observed by TRAP staining suggestive of
Paget bone disease. The VCP
R155H/+ knock-in mice replicate the muscle, bone and brain pathology of inclusion body
myopathy, thus representing a useful model for preclinical studies.
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Introduction
Inclusion body myopathy associated with Paget’s disease of
bone and frontotemporal dementia (IBMPFD, OMIM 167320) is
characterized by progressive muscle weakness, bone deformities
and extensive neuro-degeneration [1]. Muscle weakness and
atrophy of the pelvic and shoulder girdle muscles is seen in 82%
of patients at the mean age of 42 years [1–4]. Disease progression
is characterized by generalized muscle weakness resulting in
respiratory and cardiac failure in the later stages [5]. The diagnosis
of IBMPFD muscle disease is based on skeletal muscle weakness,
and the presence of rimmed vacuoles and inclusion bodies in the
muscle [1,6,7]. These inclusions have been shown to be positive
for the TAR DNA binding protein-43 (TDP-43) and ubiquitin
antibodies [8]. Although the specific function of TDP-43 is not
clear, its cytoplasmic accumulation in skeletal muscle tissue has
been used as a disease marker in human myopathies [8]. Studies in
patient myoblasts have revealed vacuoles and increased LC3 and
autophagosome formation suggestive of impaired autophagy [9].
Typically Paget’s disease of bone (PDB) seldom affects
individuals under the age of 50 years. However, PDB is observed
in 49% of IBMPFD patients [1,4] and it typically begins in the
30 s to 40 s, the mean age of onset being 42 years [10]. PDB is
caused by excessive osteoclastic activity and susceptibility to
deformities like bowing and fractures. It involves focal areas of
increased bone turnover that typically leads to spine and/or hip
pain and deformity of the long bones causing pathological
fractures on occasion. The most commonly involved bones are
the skull, vertebrae and pelvis. The diagnosis of PDB is based on
elevated concentrations of serum alkaline phosphatase (ALP),
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on skeletal radiographs or radionuclide scans.
Frontotemporal dementia (FTD) comprises about 3% of
dementias among the elderly [11–13]. In IBMPFD, premature
FTD is observed in 27% of patients with an average age of onset in
the mid 50 s [2]. It is characterized by dysnomia, dyscalculia,
comprehension deficit, paraphasic errors, and relative preservation
of memory. In later stages, patients have auditory comprehension
deficits for even one-step commands, and exhibit alexia, and
agraphia [1,4]. Affected individuals die from progressive muscle
weakness, as well as from cardiac and respiratory failure typically
in their 40 s to 60 s [1–3].
Molecular genetic studies revealed that IBMPFD is caused by
mutations in the Valosin Containing Protein (VCP) gene [7], and
thus far 19 disease mutations have been identified (for review see
[6,14]). VCP belongs to the family of type II ATPase associated
with variety of cellular activities (AAA) having two ATPase
domains [15–19]. It has been suggested to be involved in a
number of cellular activities, including homotypic membrane
fusion, transcription activation, nuclear envelope reconstruction,
post-mitotic organelle reassembly, cell cycle control, apoptosis and
endoplasmic reticulum associated degradation of proteins (ERAD)
[20–23]. Disease mutations cluster in the N-terminal domain,
which is involved in ubiquitin-binding and protein-protein
interactions [24,25]. Most of these mutated residues causing
IBMPFD are three-dimensionally located in close proximity and
potentially interact with each other [26]. These findings suggest
that these residues bind to several different adapter proteins
enabling VCP to target specific substrates for proteasomal
degradation [27,28].
To be able to study in vivo effects of identified VCP mutations,
as well as to understand the pathogenesis of IBMPFD, mouse
models have been previously generated. Both human and mouse
VCP proteins consist of 806 amino acids, and the mouse protein
differs only by one amino acid residue at position 684 when
compared to the corresponding human protein [29]. Targeted
homozygous deletion of VCP by Cre-loxP technology was
reported to result in early embryonic lethality [30] suggesting an
important role for the intact VCP expression in the development
of mouse embryos. In contrast, hemizygotes lacking one VCP
allele were apparently indistinguishable from their wild-type
littermates. On the other hand, transgenic mice over-expressing
the most common human IBMPFD mutation, R155H, under the
regulation of a muscle creatine kinase promoter demonstrated
progressive muscle weakness in a dose-dependent manner starting
at 6 months of age. These mutant mice demonstrated variation in
muscle fiber size, increase in endomysial connective tissue, and
ubiquitin positive sarcoplasmic and myonuclear vacuoles. They
also showed inclusions and small linear basophilic rimmed cracks
rather than the classic rimmed vacuoles [31]. Recently, Custer et
al. (2010) [32] reported a transgenic mouse overexpressing mutant
forms of VCP. These mice manifest muscle weakness, pathology
characteristic of inclusion body myopathy including blue rimmed
vacuoles and TDP-43 pathology. Radiological examination of the
skeleton revealed focal lytic and sclerotic regions in the vertebrae
and femur. Additionally, the brain revealed widespread TDP-43
lesions and the mice also exhibited abnormalities in behavioral
testing.
Here, we report the generation and characterization of the
VCP
R155H/+ knock-in mouse models for IBMPFD. We decided to
generate a knock-in model, since these mice express the mouse
VCP gene at endogenous level and are therefore believed to
represent a better model to study the pathology of the human
disease and to develop targeted molecular treatment. Our
preliminary results presented here are based on the analyses of
heterozygous mice for R155H. Our analyses revealed that mutant
mice show progressive muscle weakness starting at approximately
6 months of age. They also demonstrate progressive accumulation
of ubiquitin and TDP-43 positive inclusion bodies in the muscle
and brain. Muscle fibers also showed central nucleation and
altered sarcomere ultrastructure, as well as increased autophagy
and apoptosis. MicroCT analyses show increased bone activity,
cortical thickness and bone histology showed osteoclastogenesis
and increased TRAP (Tartrate Resistant Acid Phosphatase)
staining seen in Paget-like bone lesions. These results suggest that
the generated mice replicate the phenotype of human disease, and
therefore can be used to study the pathological and molecular
mechanisms underlying IBMPFD.
Results
Generation of VCP
R155H/+ knock-in mice
To generate a mouse model for human IBMPFD disease, we
created knock-in mice that are heterozygous for the most common
VCP disease mutation R155H through a Neo cassette insertion
using 129/SvEv mice (Figure 1A). These mice were back-crossed
more than six times with C57BL/6 strain before experiments were
done to make sure that the majority (.98%) of the genetic
background of generated mice was of C57BL/6 origin. C57BL/6
mice are also considered more suitable for behavioral testing due
to their higher activity level. The heterozygous mutation did not
affect the fertility or viability of mice since mutant and wild-type
mice were born in Mendelian ratio. The genotypes of all mice
were determined by PCR and RT-PCR encompassing the
mutation site, and MspI digestion. PCR genotyping and digestion
by MspI produced 274 bp and 362 bp fragments in wild-type
while the mutant alleles produced 200 and 282 bp fragments while
the mutant alleles gave 3 fragments of 636 bp, 274 bp, and 362 bp
(Figure 1B). RT-PCR analysis of the mutant mouse tissue
revealed that the mutant allele is expressed in the knock-in mice.
The MspI digestion of the PCR amplified wild-type allele resulted
in 700 bp and 282 bp fragments, whereas the mutant allele
produced a fragment of 982 bp lacking the recognition site for
MspI (Figure 1C). Western blot analysis of wild type and mutant
quadriceps, brain, heart and liver tissues revealed similar VCP
expression levels (Figure 1D,E). VCP expression by Q-RT-PCR
analyses demonstrated no statistically significant differences
between wild type (AVG DCt=5.65) and R115H knock-in
(AVG DCt=5.46) mice with a 95% CI (p=0.97).
The weight of wild-type and mutant mice were measured
weekly from 3 weeks to 15 months of age. Measurements
demonstrated that the weight of heterozygote mutant mice
developed normally when compared to their wild-type littermates
and other behavior including grooming, gait, and general activity
was indistinguishable from their wild-type littermates; however,
seizures were noted in up to 15% of the mice.
Progressive muscle weakness in the VCP
R155H/+ mouse
model
Progressive muscle weakness is one of the primary symptoms in
human IBMPFD patients [2]. Therefore, muscle strength as well
as motor coordination and fatigue were measured between ages 3
and 15 months in 3-month intervals using grip strength test and a
rotarod analysis, respectively.
The Rotarod analysis in these mice showed a 5.5% decrease at
the age of 3 months (p=0.27), 9.7% decrease at 6 months
(p=0.05), 19.3% decrease at 9 months (p=0.0072), 20.3%
decrease at 12 months (p=0.005), and 22.0% decrease at the
Knock-In Mouse Model of IBMPFD
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grip strength test, the knock-in mice demonstrated progressive
muscle weakness in forelimbs. The decrease in muscle strength was
consistent with the Rotarod analysis, showing a 2.5% decrease at 3
months (p=0.75), 3.6% at 6 months (p=0.60), 14.5% at 9 months
(p=0.028), 15.4% at 12 months (p=0.05) and 17.9% at the age of
15 months (p=0.05) (Figure 2B). There was no significant
difference in mortality between KI and WT littermates when
followed up to 15 months.
Knock-in mice share similar histopathological features as
patients
Histological analyses of muscle tissues from human IBMPFD
patients have revealed that patients’ muscle fibers accumulate
enlarged vacuoles as well as ubiquitin- and TDP-43-positive
inclusion bodies [8]. To analyze if knock-in mice mimic human
histopathology, we analyzed quadriceps tissues from 9–10 and 15-
month old wild-type and knock-in mice by H&E staining,
immunohistochemical and electron microscopy analyses. Struc-
Figure 1. Generation of the VCP
R155H/+ knock-in mice. (A) Schematic drawing of the R155H targeting strategy of the knock-in (KI) allele. The
top line shows the knock-in (KI) allele and the below line depicts the wild-type (WT) allele. The localizations of exons 1 through 5 are numbered.
Localizations of the 59 (7.9 kb) and 39 (2.1 kb) targeting sequences are indicated by dashed lines. Neomycin-cassette is marked by Neo, flanked by FRT
sites and the restriction enzyme sites are indicated as follows: K = Kpn I, Bg = Bgl II, R = EcoR I, H = Hind III. Black arrow heads flanking Neo cassette
show LoxP sites and white arrow heads show FRT sites. Black arrows flanking exon 5 indicate the locations of primers used in genotyping. (B) PCR
genotyping of isolated from mouse tail DNA and digested by Msp I produces 274 bp and 362 bp in wild-type, while mutant allele gives three
fragments of 636 bp, 274 bp and 362 bp. (C) RT-PCR-Msp I digestion analysis of mRNA isolated from mouse quadriceps shows similar expression
levels. Wild-type allele produces 700 bp and 282 bp fragments, and mutant allele produces a 982 bp fragment. Fragment sizes are shown on the
right and genotypes above. (D) VCP expression by western immunoblot in tissues: quadriceps, brain, heart and liver in wild type compared with
knock-in mouse model shows similar expression levels. (E) VCP expression by Western immunoblot in quadriceps from wild type compared with
knock-in mouse model. Beta actin was used as a loading control for these western blot analyses.
doi:10.1371/journal.pone.0013183.g001
Knock-In Mouse Model of IBMPFD
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analysis in knock-in mice. (B) Progressive impairment of muscle strength measured by grip strength meter in knock-in mice. Ages of mice are shown
in the X-axis and results are indicated in the Y-axis as relative values when compared to the wild-type mouse values. The following numbers of mice
have been used to analyze physical performance test at different time points: 3 months (25 wild-type, 9 knock-in), 6 months (51 wild-type, 20 knock-
in), 9 months (48 wild-type, 18 knock-in), 12 months (24 wild-type, 9 knock-in), and 15 months (20 wild-type, 8 knock-in). Note * * in the figure
represents p value ,0.05.
doi:10.1371/journal.pone.0013183.g002
Knock-In Mouse Model of IBMPFD
PLoS ONE | www.plosone.org 4 October 2010 | Volume 5 | Issue 10 | e13183tural analyses performed by H&E staining revealed that the
quadriceps muscle from knock-in mice show variation in fiber size
and accumulate enlarged rimmed vacuoles (Figure 3A–C). The
analysis of 1,200 cells revealed that 2.8% of muscle cells from 9–
10-month old and 15.4% of 15-month old knock-in mice were
positive for vacuoles (Table 1). Vacuoles were not found in
muscle tissues from 9–10-month old control mice, but 15-month
old control muscle demonstrated vacuolization in 3.4% of cells.
Additionally, 2.2% of muscle cells from 9–10-month old and
16.0% of 15-month old knock-in mice demonstrated centrally
located nuclei by H&E staining (Figure 3C–D) compared to
central nuclei in 7.7% of muscle cells from 15-month old control
Figure 3. Immunohistochemical analysis in the wild-type and VCP
R155H/+ knock-in mouse muscle. (A–C) Quadricep muscles from 9–10
month-old wild-type and VCP
R155H/+ knock-in mice were analyzed by H&E staining. (B) An enlarged vacuole in the mutant tissue is shown by white
arrows and (C) centrally located nuclei and rimmed vacuoles are revealed in the mutant mice shown by white arrows. (D) Quadriceps muscles from
15-month old VCP
R155H/+ knock-in mice, centrally located nuclei shown by white arrows. (E–F) Modified Gomori Trichrome staining of muscle fibers
from wild type and VCP
R155H/+ knock-in mice. Magnification: 6306. (G–L) Electron microscopy analyses of the mouse quadricep muscles.
Vacuolization and loss of myofilament organization are observed in quadriceps muscle from 10-month-old VCP
R155H/+ knock-in mice (G–I), but not in
wild-type mice (J–L). Sarcomeric direction is indicated by white double ended arrow (H,K). Swollen mitochondria are also observed in the mutant
tissue (L). Black arrows in (K) and (L) indicate accumulation of vacuoles. Size bars are shown in the lower left corner of each image. Mt =
mitochondria. Magnifications: E+H =9006,F +I =2,9506,G +J =11,5006. (N=3 WT and 3 R155H animals).
doi:10.1371/journal.pone.0013183.g003
Knock-In Mouse Model of IBMPFD
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presence of rimmed vacuoles in the R155H knock-in mouse when
compared to wild-type controls (Figure 3E–F).
Ultrastructural analyses of quadriceps muscle showed disorga-
nized sarcomeres and vacuolization of muscle fibers in the knock-
in mice as demonstrated in 12-month old mice (Figure 3G–I).
Mutant muscle also showed abnormal swelling of mitochondria.
The ultrastructural changes of the quadriceps from 9–10-month
old mutant mice were milder when compared to older mice
(Figure 3J–L).
Characterization of muscle pathology in knock-in mice
To further characterize the muscle pathology, we stained fixed
muscle sections with VCP-, ubiquitin- (FK1), and TDP-43-specific
antibodies. Four percent (9–10-months old) and 9.0% (15-months
old) of mutant cells had inclusion bodies that were positive for the
TDP-43 and ubiquitin-specific antibodies, versus 2.1% in 15-month
old control mice, (Figure 4 and Table 1). The mutant knock-in
muscle sections revealed strong expression of FK1 and TDP-43
(Figure 4D–F) as compared to the wild-type controls (Figure 4A–
C). Western blotting analysis of two separate litter-matched wild-
type and knock-in mice revealed that the mutant muscle had more
TDP-43 and ubiquitinated (FK1 marker) proteins (Figure 4G).
These inclusions were negative for the VCP antibody suggesting
that mutant VCP does not accumulate in the mutant muscle cells.
Autophagy and apoptosis is increased in knock-in mice
muscle tissue
Autophagy is a process that degrades long-lived proteins and
cytoplasmic components within vesicles which deliver the contents
Table 1. Vacuoles, inclusion bodies and centrally located nuclei in 9–10 month and 15 month old wild-type and R155H knock-in
mouse muscle.
Histological
Methodology Observed organelles Results N=3 Age (months) Cells counted
WT (%) R155H (%) WT/R155H
H&E Vacuoles 0 2.7560.432 p,0.05 9–10 1,200/1,200
TDP-43/Ub IHC Inclusion bodies 0 3.9660.331 p,0.05 9–10 1,386/1,386
H&E Centrally located nuclei 0 2.1660.144 p,0.05 9–10 1,200/1,200
H&E Vacuoles 7.6661.01 15.42862.41 p,0.05 15 1,200/1,200
TDP-43/Ub IHC Inclusion bodies 3.41060.38 9.0060.902 p,0.05 15 1,200/1,200
H&E Centrally located nuclei 2.0860.38 16.01060.99 p,0.05 15 1,200/1,200
H&E - Hematoxylin and Eosin; Ub – Ubiquitin; TDP-43 – TarDNA Binding Protein-43; IHC- Immunohistochemical staining; WT- Wild Type; R155H –
Heterozygous knock in.
doi:10.1371/journal.pone.0013183.t001
Figure 4. Immunohistochemical analysis and protein expression in the wild-type and VCP
R155H/+ knock-in mouse muscle. (A–F)
Immunohistochemical analysis of quadriceps muscles from 9–10 month old wild-type (A–C) and VCP
R155H/+ knock-in mice (D–F) were stained with a
ubiquitin-specific FK1 antibody (A,D) and a TDP-43-specific antibody (B,E). (C) shows the overlay of (A) and (B), and (F) is the overlay of (D) and (E).
Ubiquitin- and TDP-43-positive, cytoplasmic inclusion body is shown by an arrow in (D–F). Nuclei were stained with DAPI. Magnification: 6306.). (G)
Expression of TDP-43 and ubiquitinated proteins. Proteins were harvested from the quadriceps muscle of 2 littermates of wild-type and knock-in mice
and analyzed by Western blotting using TDP-43 (upper panel) and ubiquitin/FK1 (lower panel) antibodies. Each membrane was re-probed with actin
to confirm equal protein loading in each lane. Protein bands are indicated on the left and molecular weights of marker bands for the ubiquitin blot on
the right. Genotypes are shown above. Wild-type and knock-in samples are from two litters (indicated above the figure) (N=4 WT and 4 R155H
animals).
doi:10.1371/journal.pone.0013183.g004
Knock-In Mouse Model of IBMPFD
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as a marker for autophagy. There are three human autophagy
forms of LC3B and LC3C). Upon activation of autophagy, the
18 kDa cytosolic LC3 (LC3B-I) undergoes proteolytic cleavage
followed by a lipid modification and is converted to the 16 kDa
membrane-bound form (LC3B-II), which is specifically localized to
the autophagosomal membranes. The conversion from LC3B-I to
LC3B-II is used as a sensitive marker for autophagy in cells. Using
myoblasts obtained from patients with VCP associated IBM [9,33]
we observed accumulation of enlarged vacuoles as well as other
several cellular dysfunctions in patients’ myoblast cells versus
normal control myoblasts. Western blotting analysis demonstrated
that the protein lysates extracted from the mutant cells have
significantly increased amount of LC3B-II when compared to the
wild-type cell lines. Thus, to analyze if autophagic processes were
also disrupted in the knock-in mice, we analyzed the expression of
the LC3B-II protein. Muscle cells from the knock-in mice
exhibited increased LC3B-II staining, which was concentrated in
the vesicular organelles throughout the cytoplasm compared to
WT (Figure 5A,B). Western blot analysis from knock-in
VCP
R155H/+ quadriceps tissue lysates demonstrated a significantly
increased amount of LC3B-II when compared to the wild-type
animals (Figure 5C).
Mutations in the VCP gene havebeen shownto trigger cell death
with apoptotic features, whereas expression of wild-type protein has
been suggested to have an anti-apoptotic effect [34,35,36]. These
findings suggested that mutated VCP may also cause apoptosis in
mouse muscle expressing the R155H disease mutation. To
elucidate if this hypothesis holds true, we analyzed mouse
quadriceps tissues for apoptosis by measuring caspase-3 activity
and TUNEL staining. Mutant muscle showed 2.8-fold increase in
caspase-3 activity when compared to the wild-type muscle (wild-
type: 0.629 pmol/mg protein/hr; knock-in: 1.755 pmol/mg protein/
hr) suggesting that mutant tissue exhibits significantly increased
apoptosis (p=0.007) (Figure 5F). These results were confirmed by
TUNEL-staining of quadriceps sections, which showed increased
number of apoptotic nuclei as compared with WT (wild-type; 6.9%
and knock in: 28.9%, P,0.05) (Figure 5D,E). Some of the
apoptotic nuclei were centrally located in the knock-in muscle.
Bone pathology in VCP
R155H/+ knock-in animals
resembles Paget’s Disease of Bone
To further characterize the bone pathology of knock-in mice we
analyzed bone morphology by micro CT imaging. The micro CT
images showed radiolucency of the proximal tibia and distal
femurs in some knock-in mice (Figure 6A,B). The Bone Surface
area/Bone Volume (BS/BV), Trabecular Space (Tb.Sp) was not
different, but significantly decreased Trabecular Pattern Factor
(Tb.P.F) and increased Cortical wall Thickness (C.Th) in knock-in
mice was observed compared to WT mice (Table 2).
Histology of the tibiae and the centrum of the VCP
R155H/+
mouse vertebra, when compared to wild-type, clearly showed
Figure 5. LC3-II staining, protein expression and apoptosis detection in the wild-type and VCP
R155H/+ knock-in mouse quadriceps.
(A–B) Quadricep muscles from 9–10 month old wild type and VCP
R155H/+ knock-in mice were stained with an LC3-II-specific antibody. Nuclei were
stained with DAPI (Magnification: 6306). (C) Protein expression of LC3-II is increased in knock in mice as compared with wild type litter mates. (D–E)
DAPI and TUNEL staining of the quadriceps section from a wild-type and VCP
R155H/+ knock-in mouse models (N=3 WT and 3 R155H animals).
Apoptotic nuclei of the mutant tissue are shown by white arrows. Magnification: 4006. (F) Caspase-3 activity was measured from the quadriceps
muscle lysates of wild-type and VCP
R155H/+ knock-in mice. Specific activities are shown in the Y-axis and genotypes in the X-axis (N=4 WT and 4
R155H animals).
doi:10.1371/journal.pone.0013183.g005
Knock-In Mouse Model of IBMPFD
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further study osteoclast formation in our VCP
R155H/+ mice, we
performed TRAP (Tartarate Resistant Acid Phosphatase) staining
of the tibia and 6th lumbar vertebra sections. A similar structure
pattern and osteoclast distribution in VCP
R155H/+ and wild-type
without TRAP staining was noted (Figure 6C–D). TRAP staining
of VCP
R155H/+ tibia and centrum tissues demonstrated increased
bone and osteoclasts as compared with wild-type at 106
(Figure 6C–D).
To study osteoclast formation in knock-in mice, bone marrow
derived macrophages (BMDMs) and spleen-derived cells from
wild-type and knock-in mice were cultured for 9 days in the
presence of 10 ng/ml M-CSF and varying concentrations of
RANKL (0, 0.5, 1, 5, 10 and 50 ng/ml). The cells were then fixed
and stained for TRAP activity. Cultures of BMDM cells from
knock-in mice formed significantly more osteoclasts (OCLs) in
response to RANKL than wild-type (WT) BMDM cultures
(Figure 6E–G), which is similar to bone marrow cultures from
PDB patients. BMDM cultures from the R155H mice had
significantly greater numbers of OCLs for 1, 5 and 10 ng/ml
RANKL, but at 50 ng/ml the statistical significance was lost. Like
OCLs formed in PDB patients BMDM cultures from the
VCP
R155H/+ mice contain a population of giant OCLs that have
an increased number of nuclei per OCL compared to wild-type
mice (Figure 6G). These giant cells were not seen in any wild-type
culture during the course of these experiments and the giant OCLs
were a sub-population of OCLs in the mutant BMDM and spleen
cultures, where most multi-nuclear TRAP positive OCLs were of
similar size as those in the wild-type cultures. The increase in
TRAP positive multinucleated cells observed in knock-in mice
suggested increased osteoclastogenesis associated with Paget-like
disease of bone (Figure 6H).
Brain tissue analysis
Similar inclusion pathology has been reported in patients’ brain,
including neocortex, as well as in limbic and subcortical nuclei.
Histological analyses of the brain tissues from 9–10-month and 15-
month old mutant mice did not show any overt histological signs of
degeneration in H&E staining (Figure 7A,B). Ionized Calcium-
binding adaptor molecule 1 is expressed selectively in microglia
and is upregulated during activation of cells. Staining of the frontal
cortex showed increased IBA1 expression in the mutant versus
wild type mice (Figure 7C,D). However, the immunohistochem-
ical staining of frontal cortex from 15-month old knock-in mice
demonstrated increased TDP-43 and ubiquitin-positive inclusions.
In contrast to muscle samples, these cortical inclusions were also
positive for the VCP antibody. Staining with Ubiquitin and VCP
demonstrated cytoplasmic inclusions in the frontal cortex in the
mutant mice as compared with the WT (Figure 8A,B). Similar
findings were observed in the mutant and WT mice with FK1- and
TDP-43-specific staining (Figure 8C,D). The TDP-43 inclusions
showed nuclear clearance and cytoplasmic accumulation in the
knock-in mouse brains whereas the TDP-43 inclusions showed
nuclear localization in the cortex of control knock-in mice
(Figure 8E,F). These results were confirmed by western blot
analyses of VCP, TDP-43 (Figure 8G,H). GFAP (glial fibrillary
acidic protein) and pro-apoptotic markers including p53 upregulated
modulator of apoptosis (PUMA) and Bcl-2–associated X protein
(BAX) were analyzed by western blot analysis and no significant
differences were found in the R155H versus WT mice (Figure 8G).
6- and 15-month old knock-in mice do not show
impaired short term memory, but show seizures
To analyze if knock-in mice exhibit dementia, we performed a
novel object recognition test with the 6- and 15-month old mice.
Values closer to 50% suggest that the mice show no object
preference, whereas values closer to 100% suggest that the mice
prefer the novel object. No significant difference in novel object
recognition test was observed between 6-month old wild-type and
knock-in mice. The memory index of the 15-month old
heterozygous mice was 67.8%, with the wild-type mice scoring
55.2% (p=0.09) suggesting that the short term memory of the 15-
month old knock-in mice is not impaired.
Unexpectedly, we observed complex seizures in the heterozy-
gous mice. These seizures started with partial, limbic behavior,
followed by tonic-clonic seizures (clonic wild running and
somersaulting was also observed) and ended by a typical post-
ictal quiescent phase including repetitive behavior (grooming).
Four heterozygous mice out of 27 (14.8%) developed seizures at
the age of 9 months, and another three out of an additional 30
(10%) at the age of 12 months. The seizures were precipitated by
moving or tapping on the cage of these mice, but they did not
appear to shorten the lifespan of the mice. Seizures did not shorten
the life span of the mice. Seizures were not observed in wild-type
age-matched littermates up to the age of 15 months (https://
webfiles.uci.edu/xythoswfs/webui/_xy-6368126_1-t_VqHhatlP).
Figure 6. Bone micro CT imaging, histology and OCL formation of VCP
R155H/+ and wild-type mice. (A–B) micro CT images showing
sclerotic lesions at anterior tibia and posterior femur shown by white arrows in 15-month old knock-in mice. (C–D) Transverse sections of decalcified
6
th lumbar vertebra, white arrowheads indicate red colored TRAP-positive osteoclasts (Magnification 106). (E–G) OCLs formed from non-adherent
marrow cell cultures for WT or VCP
R155H/+ cultured for 9 days in the presence of 10 ng/ml M-CSF and varying concentrations of RANKL. The cells were
then fixed and stained for TRAP activity. Results represent TRAP positive cells containing $ three nuclei and are expressed as the mean 6 SEM for
duplicate cultures.*P,0.05 compared with results from wt cell cultures. MNC= multi-nuclear cell. (G) Large TRAP positive multinuclear OC-like cell
from knock-in bone marrow derived macrophages (BMDM). Differentiated in 100 ng/ml RANKL and 50 ng/ml M-CSF then fixed and TRAP stained on
day 9 of differentiation. (H) Osteoclastogenesis cytokine sensitivity was determined with increasing concentrations of RANKL. TRAP-expressing multi-
nucleated OCs was scored (N=4 WT and 4 R155H animals).
doi:10.1371/journal.pone.0013183.g006
Table 2. Bone Morphometry in WT and R155H KI mouse
models.
Bone Morphometry
Parameters Wild Type R155H KI
Bone Volume/Total Volume 0.6860.17 0.760.12 p=0.590
Bone Surface Area/Bone Volume 20.165.9 17.263.2 p=0.062
Trabecular Thickness 0.10760.03 0.1260.02 p=0.170
Trabecular Number 6.5261.98 6.0261.4 p=0.360
Trabecular Space 0.0760.11 0.05360.031
p=0.470
Trabecular Patter Factor 5.0563.14 2.7561.74 p=0.007
Cortical Thickness 1.7760.32 2.3560.35 p=0.0001
Significant differences were identified in the trabecular pattern factor and
cortical wall thickness.
doi:10.1371/journal.pone.0013183.t002
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VCP is involved in a number of cellular functions, most of which
are related to ubiquitin-proteasome dependent proteolysis [24,37–
40]. It is highly conserved in evolution suggesting an essential role
for normal cellular functions in both unicellular (yeast) and multi-
cellular organisms [41–43]. The finding that inhibition of VCP
expression promotes apoptosis [44] suggests that intact VCP is
indispensable for normal development and cell survival. Our recent
studies of myoblasts associated from subjects with VCP mutations
demonstrated accumulation of enlarged vacuoles [9]. Despite
intense investigations, the disease mechanisms underlying IBMPFD
are yet to be clarified. Our knock-in mice exhibit muscle weakness,
vacuoles and inclusions inthemusclefibers,Paget like bone changes
on microCT and histology and typical brain pathology of IBMPFD.
Collectively, these findings suggest that our mouse model provides
an important experimental platform for probing the underlying
mechanisms responsible for this unique disease. The following
discussion addresses each of these key findings.
VCP
R155H/+ myopathy and its correlation to that in humans
To be able to elucidate tissue and cellular pathology of IBMPFD,
we have generated a knock-in mouse model that expresses the most
common VCP disease mutation R155H at endogenous level. By
creating a mouse model that mirrors the human disease and by
studying the muscle, brain, bone and other organs in the mice, we
hope to be able to understand the enormous clinical variability in
IBMPFD patients. Furthermore, our current mice provide us with
the potential of breeding new mouse models to better understand
the increased risk of FTD observed in those with both an APOE4
allele and mutant VCP phenotype [38].
Previous animal models for IBMPFD include the knock-out
mouse model reported by Muller et al (2007) [30]. Mice with
homozygous deletion of VCP did not survive to birth, but died at a
peri-implantation stage, whereas hemizygote mice were indistin-
guishable from their wild-type littermates. When hemizygote mice
were mated, no homozygous mice were ever seen endorsing an
important role for VCP in normal development of mouse
embryos. Transgenic mice overexpressing R155H VCP under a
muscle-specific promoter, reported by Weihl et al (2006) [31],
demonstrated muscle weakness, and slit-like vacuoles. Additional-
ly, Custer et al. have generated transgenic mice expressing VCP/
p97 with the R155H and A232E mutations shown to develop
pathology of the muscle, bone, and brain exhitibing similar
characteristics seen in humans with IBMPFD [32].
The VCP
R155H/+ allele in the knock-in mouse model that we
have created expresses the mutant allele at physiological levels as
seen in the patients and thus overcomes the problems of over
expression. Our knock-in mice demonstrates several phenotypic
andhistologicalchanges,all ofwhicharetypicalofhumanIBMPFD
patients, who develop muscle weakness at the mean age of 42 years.
Progressive deterioration of muscle strength of knock-in mice
mirrors the development of late onset muscle weakness reported in
patients [1,3,45] and transgenic mice expressing R155H VCP [31].
Histological analyses of musclefrom our knock-in mouse model of
IBMPFD reveal vacuolization and central nucleation TDP-43-and
ubiquitin-positive sarcoplasmic inclusions [8] thus, closely matching
the histopathology of human IBMPFD patient muscle. Electron
microscopic studies of the mutant muscle showed disorganization
and vacuolization of the sarcomeres [46–48] and significant swelling
of mitochondria associated with increased apoptosis, which is not
only seen in our knock-in mice and human IBMPFD, but also in
yeast [49] supporting the high evolutionary conservation of VCP
from yeast to human (70%) [41] and suggesting that energy
metabolism of affected muscle may be disturbed.
Bone remodeling in the VCP
R155H/+ mouse model:
correlation to bone pathology in IBMPFD patients
PDB is characterized by abnormal bone remodeling, osteolytic
lesions, bone deformities and pathologic fractures (in severe cases).
Figure 7. Immunohistochemical brain staining of the wild-type and R155H knock-in mouse. (A–B) H&E staining of 15 month old wild type
and knock-in mouse of hippocampus and neuronal injury shown by white arrows (Magnification 4006). (C–D) IBA1 staining of frontal cortex from
wild-type and R155H knock-in mice shown by white arrows Magnification: 6306(N=3 WT and 3 R155H animals).
doi:10.1371/journal.pone.0013183.g007
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of bone, followed shortly thereafter, by osteoblast hyperactivity.
The osteoblasts are normal morphologically, but deposit new bone
in a disordered manner resulting in Pagetic lesions. The new
disorganized bone is of poor quality leading to bowing and
occasional fractures. In the more advanced stages of Paget disease,
rapid bone formation predominates. The lesions become sclerotic,
bone marrow is replaced with vascular and fibrous tissue and
increase in bone thickness. Using histochemical stains and
microCT imaging, we compared the bone findings of our knock-
in mice to the typical findings in human Paget’s disease. The
microCT images of knock-in mice show radiolucency of the distal
femurs and proximal tibias which is consistent with bone
morphometric analysis of our knock-in mice. Osteoclasts in
Paget-like lesions are increased in both number and size indicated
by TRAP immunostaining. In vitro studies of bone marrow
derived macrophages from knock-in mice femurs and tibia
revealed hyper responsiveness to RANKL. Finding that knock-in
mutant mice can generate giant osteoclasts is an important result,
since this cellular phenotype resembles the human Pagetic
osteoclast phenotype. The localized lesions seen in the mice also
resemble the patchy distribution of Pagetic lesions in patients. The
IBMPFD mouse promises to be a good model for human Paget
disease of the bone for future therapeutic studies.
Our studies suggest that our generated knock-in mouse model
for IBMPFD represents an excellent model for the human disease.
Our mice express the R155H mutant VCP gene at an endogenous
level compared to previous models which overexpresses the
mutant allele. Our knock-in mice provide an opportunity to study
the molecular pathways regulating the myriad aspects of VCP
disease and thus, may aid in the development of novel strategies
for treatments of diseases with similar pathogenesis.
Our recent studies in IBMPFD patient myoblasts exhibit
increased apoptosis when analyzed by caspase-3 assays and
TUNEL staining as well as increased autophagy [9]. We replicated
our studies in the knock-in mouse muscle, and observed similar
findings. Autophagy is a process that functions as a stress response
that is upregulated by starvation, oxidative stress, or other harmful
Figure 8. Immunohistochemical staining and protein expression of the wild-type and R155H knock-in mouse brain. (A–B) Co-
localization of VCP- and ubiquitin-specific antibodies in 15-month old wild type and R155H knock-in mice. (C–D) Co-localization of FK1- and TDP-43-
specific antibodies in wild type and R155H knock-in mice from frontal cortex. Inclusion bodies are shown by white arrows. Nuclei were stained with
DAPI (blue). Magnification: 6306(N=3 WT and 3 R155H animals). (E–F) Co-localization of VCP- and TDP-43-specific antibodies of wild type and R155H
knock-in mice from frontal cortex. Inclusion bodies are positive for VCP and TDP-43 antibodies are shown by white arrows and inset. Nuclei were
stained with DAPI. (G–H) Protein expression of VCP, TDP-43, GFAP, PUMA, BAX and ubiquitin have been analyzed by Western immunoblot from WT
and R155H KI mutant whole brain extracts (N=4 WT and 4 R155H animals). Beta actin was used as loading controls for these Western blot analyses.
doi:10.1371/journal.pone.0013183.g008
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important housekeeping and quality control functions that
contribute to health and longevity (for review, see [50–53]. In
addition, impaired autophagic degradation contributes to the
pathogenesis of several human diseases including muscle diseases
and lysosomal storage disorders. Danon disease is an example of a
human myopathy that is characterized by accumulation of
autophagic vacuoles in the heart and skeletal muscle [54]. A
mouse model for Danon disease exhibits similar histological and
phenotypical features to human patients showing massive
accumulation of autophagic vacuoles in several tissues, including
skeletal muscle and heart [55]. Vacuoles are seen in the muscle of
the heterozygotes and were very prominent in the cardiac muscle
in the homozygotes. Mitochondria are a main target for
autophagic degradation in muscle diseases resulting in reduced
mitochondrial function, which leads to defective energy metabo-
lism and reduced contractility [56]. Therefore, increased autop-
hagosome formation as exhibited by LC3-II accumulation, as well
as muscle weakness seen in both our VCP
R155H/+ knock-in mice
and IBMPFD patients, is consistent with other myopathic
conditions suggesting a common pathogenesis. Both knock-in
mice and IBMPFD patient histology indicate not only induction of
autophagy, but also disruption of the autophagic maturation
process. The current hypothesis is that immature autophagosomes
accumulate in tissues secondary to impaired lysosome-autophago-
some fusion further contributing to tissue pathology.
Brain histopathology in the VCP
R155H/+ mouse model
Frontotemporal dementia develops in 27% of human patients at
the mean age of 57 years [2]. Although no short term memory
deficiencies were observed in knock-in mice, the development of
brain histopathology was similar to that of human patients. We
observed accumulation of TDP-43-, ubiquitin-, and VCP-positive
inclusions in the 15-month old knock-in brain, but not in 10-
month old brain, mimicking the delayed development of human
brain pathology. Immunohistochemical staining of frontal cortex
and hippocampus showed increased nuclear clearance and
cytoplasmic accumulation of TDP-43 inclusions in the knock-in
mouse brains similar to the pathology in humans with VCP
disease, in contrast to the nuclear localization in the cortex and
hippocampus of control mice. In addition, inclusions stain positive
for TDP-43, VCP and Ubiquitin [57]. The ionized calcium
binding adaptor protein 1 (IBA1) is thought to play a role in
regulating the function of microglia and considered to be specific
biomarker. Microglial primary function involves maintenance of
normal tissue brain homeostasis and production of variety of
neurotransmitters [58]. Higher levels of IBA 1 expression was
observed in frontal cortex of knock-in mouse. Hence homeostasis
of brain and neurotransmission may be altered. Glial fibrillary
Acidic protein (GFAP) is astrocyte marker and reveals morpho-
logical changes during cell injury or adverse conditions [59]. The
immunohistochemical staining and western immunoblot analysis
have shown no changes in both knock- in mouse and control. The
morphological changes in astrocytes and astrogliosis are not
involved in TDP pathology of knock-in mouse. The apoptotic
pathway has not been induced in brain as there is no alteration in
pro-apoptotic markers (PUMA, BAX).
Interestingly, we observed spontaneous seizures in 12.3%
knock-in mice. Since seizures are not reported in human IBMPFD
patients, these findings combined with the observation that VCP is
abundantly expressed in hippocampus [60] propose an important
role for VCP in the hippocampal region. We observed neuronal
injury in the hippocampus CA3 region (Figure 7 A,B) of knock-in
mouse. Although seizures are not seen in VCP disease, they are a
feature of early onset dementia and frontotemporal dementia [61].
As we study additional families and expand the phenotype of this
multifaceted disease, we predict that patients/families will be
identified in which seizures are an associated manifestation.
Materials and Methods
Ethics Statement
All experiments were done with the approval of the Institutional
Animal Care and Use Committee (IACUC) of the University of
California, Irvine (IACUC Protocol #2007–2716), and in accor-
dance with the guidelines established by the NIH. Animals were
housed in the animal facility of the University of California, Irvine,
and maintained under constant temperature (22uC) and humidity
with a controlled 12:12-h light-dark cycle. Mice had free access to
mouse chow and 0.9% NaCl drinking water. Animal welfare
including objective measures such as physiological and behavioral
indicators were monitored and recorded four times a week. To
ameliorate any suffering of animals observed throughout these
experimental studies, mice were euthanized by CO2 inhalation.
Generation of the VCP
R155H/+ knock-in mouse model for
IBMPFD
Mouse genomic VCP fragment with 7.9 kb of upstream
homology sequence and 2.1 kb of downstream homology
sequence was subcloned into a targeting vector. Site-directed
mutagenesis using Quick-Change XL Site-Directed Mutagenesis
Kit (Stratagene, La Jolla, CA) was used to introduce the R to H
mutation at amino acid position 155. The knock-in mouse model
with the R155H VCP mutation was generated at the inGenious
Targeting Laboratory, Inc. (Stony Brook, NY). 10 mg of the
targeting vector was linearized by NotI (New England BioLabs
Inc., Ipswich, MA) and then transfected by electroporation into
129/SvEv embryonic stem (ES) cells. After the selection in the
G418 antibiotic (Gibco, Carlsbad, CA), surviving clones were
expanded for Southern blotting analysis, and recombinant ES cells
were injected into 129/SvEv blastocysts, which were transferred to
the uteri of pseudopregnant females. Resulting chimeras were
mated to 129/SvEv mice to produce F1 generation of mutant
mice. Before experiments, generated heterozygous VCP
R155H/+
knock-in mice were back-crossed at least six times with C57BL/
6JEiJ. Therefore, more that 98% of the genome is expected to
originate from C57BL/6JEiJ. Littermates were used in every
experiment.
Validation of the VCP
R155H/+ knock-in mice
For PCR genotyping, DNA was extracted from mouse tail
samples using a DirectPCR Lysis Reagent (Viagen Biotech Inc.,
Los Angeles, CA) following the manufacturer’s guidelines. Tail
DNA samples were subjected to PCR using the following primers:
Forward: 59-gcc tct ctg aag gat aat gtg g-39; Reverse: 59-atg gga ttg
ggt tct ttc aa-39. PCR products were digested with MspI (New
England BioLabs, Inc.) and the results were analyzed by agarose
gel electrophoresis.
The expression of the mutant allele was confirmed by RT-PCR
using the following primers in the PCR reactions: Forward: 59-cac
ggt gtt gct aaa agg aaa gaa aag; Reverse: 39-ctg aag aat ctc caa acg
tcc tgt agc, after the RT reactions with the Reverse primer.
Amplified products were digested with MspI (New England
BioLabs Inc., Ipswich, MA) and the results were analyzed by agarose
gel electrophoresis. Total mRNA was isolated from quadriceps of
mice (4 from knock-in and 4 from wild type) using TRIzol reagent
(Invitrogen)) followed by the RNeasy Mini Kit with on-column
DNase treatment. cDNA was prepared from total RNA (500 ng per
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Frederick, MD), and 50 ng of cDNA in RT2 qPCR Master Mix (SA
Biosciences) was applied to each well of the 384-well array, according
to the manufacturer’s instructions. Above primer sequences were
used for both the RT-PCR and qRT-PCR. After running the Q-RT-
PCR on Roche Light Cycler 480 instrument, the results were
analyzed by using SA Biosciences online software (http://www.
sabiosciences.com/pcr/arrayanalysis.php).
Measurements of weight, motor coordination and
muscle strength
To follow the development of body mass, the weight of every
knock-in and wild-type mouse was measured weekly. Motor
coordinationandfatigue wereassessed bya rotarod(Med Associates
Inc., St. Albans, VT) accelerating speed analysis. The rotarod test
was performed for all existing mice at the age of 3 months (25 wild-
type, 9 knock-in), 6 months (51 wild-type, 20 knock-in), 9 months
(48 wild-type, 18 knock-in), 12 months (24 wild-type, 9 knock-in),
and 15 months (20 wild-type, 8 knock-in). Mice were placed on the
rotarod, which accelerates from 4 to 40 rpm in 5 minutes. The
results were recorded as a mouse dropped down from the rotarod
for the first time. Mice went through three trials with 45- to 60-
minute inter-trial intervals on each of two consecutive days. Data
from the previous two day trial were used to set the baseline.
Statistical analyses were performed by student’s t-test.
Muscle strength of the forelimbs of mice was measured by a Grip
Strength Test using a Grip Strength Meter apparatus (TSE Systems
Gmbh, Hamburg, Germany) for the same mice as in the Rotarod
test.Mice were held from thetipofthe tail above the grid andgently
lowered down until the front paws grasped the grid. Hind limbs
were kept free from contact with the grid. The animal was brought
to an almost horizontal position and pulled back gently but steadily
until the grip was released. The maximal force achieved by the
animal was recorded. Each animal underwent 5 testings.
Novel object recognition test
Short term memory of 6-month old mice (6 wild type and 6
knock-in) and 18-month old mice (5 wild-type and 5 knock-in) was
analyzed by novel object recognition test. In phase I (habituation),
mice were habituated for three consecutive days for 20 min each
day in their cages. During this habituation phase, no objects were
introduced. On day 4, mice were familiarized with identical
objects in their clean testing cages for 15 min. These objects were
not used in the ensuing sessions. The novel object recognition test
was performed the following week.
In phase II (object recognition test), mice were placed in
separate cages, each containing two identical objects. Mice were
allowed to explore the objects for 5 min, after which the mice were
returned to their own cages for a 5-min retention period.
Thereafter, mice were returned to their new testing cage. Upon
return, one of the objects had been replaced with a new object.
The mice were then allowed to explore for 3 min. All testing
activities were videotaped and following well-documented proce-
dures specifically designed for object memory tests [62].
The scoring of data was done by reviewing the recorded tapes by
measuring the time mice spent with familiar and novel objects. The
timing did not begin before until mice moved from their original
position. Additionally, exploring was scored if the mouse was within
one inch of the object. Activities such as chewing, grooming, or
standing farther than one inch from the object were not scored. The
memory index (MI) was determined using the formula MI = Tn
6100/(Tn + Tf), in which Tn = time spent with the novel object,
and Tf = time spent with the familiar object.
Histological analyses of muscle tissue
The histopathology of knock-in mice was analyzed by
hematoxylin and eosin (H&E) staining, immunohistochemistry
and electron microscopy. 9–10 and 15-month old mice (3 wild-
type and 3 knock-in) were euthanized by cervical dislocation,
dissected quadriceps and brain tissues were mounted in a cryo-
sectioning mounting media (Electron Microscopy Sciences,
Hatfield, PA) and stored at 280uC before sectioning at 5–
10 mm. For H&E staining, cryo-sections were fixed in 10%
formalin for 30 min and washed 3 times with PBS. Thereafter,
sections were incubated in hematoxylin (Poly Scientific, Bayshore,
NY)/glacial acetic acid (Sigma-Aldrich, St. Louis, MO)-solution
for 3 min, rinsed with deionized water for 5 min, dipped 8–12
times into acid ethanol, rinsed 2 times for 1 min with tap water,
and once with deionized water for 2 min. Thereafter, slides were
stained with eosin (Poly Scientific) for 30–45 sec, incubated in
95% ethanol 3 times for 5 min, 3 times in 100% ethanol for 5 min,
and finally 3 times in xylene for 15 min. Slides were mounted with
Permount (Fisher Scientific, Pittsburgh, PA) and results were
analyzed by a light microscope (Carl Zeiss, Thornwood, NY) using
an AxioVision image capture system (Carl Zeiss).
For immunohistochemical analyses of mouse tissues, fixed
sections were blocked with 5% fetal bovine serum/PBS solution
for 30 min. The sections were immunostained with TDP-43
(Abcam, Cambridge, MA), FK1 (BIOMOL), VCP (Affinity
BioReagents, Golden, CO), LC3 (Novus Biologicals, Littleton,
CO), IBA1 (Ionized calcium binding adaptor molecule 1,WAKO,
Richmond, VA), GFAP (Glial fibrillary acidic protein, DAKO,
Denmark), BAX (Cell Signaling, Danvers, MA), and PUMA (Cell
Signaling, Danvers, MA) antibodies overnight at 4uC, and washed
3 times with PBS. Fluorescein-conjugated secondary antibodies
(Sigma-Aldrich, St. Louis, MO) were incubated for 1 hour at
room temperature. Sections were washed three times with PBS
before mounting in DAPI-containing mounting media (Vector
Laboratories, Inc., Burlingame, CA). Modified Trichrome Gomori
staining was performed with Gomori Trichrome Stain on
quadriceps tissue sections using routine methods. Results were
analyzed by a light microscope (Carl Zeiss) using an AxioVision
image capture system (Carl Zeiss).
For electron microscopic studies, quadriceps muscles from three
9–10 and 12-month old knock-in and wild-type mice were fixed in
4% paraformaldehyde/0.1% glutaraldehyde/0.1 M PB. Then
tissue samples were fixed in 1% glutaraldehyde overnight and in
1% Osmium for 1 h at 4uC. Samples were embedded in Eponate
12 resinin at 65uC for 24–36 h and serially dehydrated in ethanol.
Ultra-thin (60,80 nm) sections were cut with a diamond knife.
Sections were stained in 1% uranyl acetate for 30 min, followed by
lead citrate staining for 7–10 min. Sections were examined by the
Philips CM10 transmission electron microscope (Amsterdam, The
Netherlands), and electron micrographs were taken with a Gatan
UltraScan US1000 digital camera (Philips).
Protein expression analyses by Western blotting
To determine the expression levels of proteins in the mouse
muscle, quadriceps muscle tissues were subjected to Western
blotting. Muscle samples from 9–10-month-old wild-type and
knock-in mice (4 wild-type and 4 knock-in mice from four litters, of
which only 2 litter sets are shown in this manuscript) were
harvested and lysed by homogenization and sonication in a RIPA-
buffer (50 mM Tris pH 8.0, 150 mM NaCl, 1% igepal, 0.5%
deoxycholic acid, 0.1% SDS; all from Sigma-Aldrich) supple-
mented with protease inhibitors (Halt Protease Inhibitor Cocktail;
Pierce, Rockford, IL). Protein concentrations were determined
using the Bio-Rad Protein Assay kit (Bio-Rad, Hercules, CA)
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proteins were separated on SDS-PAGE gels, and the expression
levels of proteins were analyzed by Western blotting using TDP-43
(Abcam, Cambridge, MA) and FK1-specific antibodies (BIOMOL
Research Labs, Plymouth Meeting, PA). Equal protein loading
was confirmed by a Beta-Actin antibody (Santa Cruz Biotechnol-
ogy, Santa Cruz, CA) staining.
Apoptosis
Apoptosis in mouse tissue samples was analyzed by the
DeadEnd Fluorometric TUNEL System (Promega, Madison,
WI) and by the Colorimetric CaspACE-3 Assay System (Promega).
For TUNEL staining, muscle cryo-sections from two 10-month old
VCP
R155H/+ knock-in mice and two wild-type littermates were
generated as described above. Sections were fixed with 4%
paraformaldehyde, washed with PBS, permeabilized with 0.2%
Triton X-100 (Sigma-Aldrich, St. Louis, MO) solution in PBS,
rinsed with PBS, equilibrated with equilibration buffer, and
labeled with nucleotide mix/rTdT enzyme solution. After washing
with 26 SSC, cells were washed with PBS and mounted in
Vectashield with DAPI. The results were analyzed by immuno-
fluorescence microscopy (Carl Zeiss). For caspase-3 assay, muscle
proteins were extracted with cell lysis buffer from the same mice as
described above. To complete the lysis, samples were frozen and
thawed three times after homogenization, followed by centrifuga-
tion. Supernatants were transferred into a fresh tube and protein
concentrations were determined using the Bio-Rad Protein Assay
kit (Bio-Rad, Hercules, CA). Equal amount of proteins were
analyzed in 96-well plates in triplicate, in the presence of 2%
DMSO, 100 mM DTT, and 0.2 mM DEVD-pNA substrate.
Reaction mixtures were incubated at 37uC for 4 h and the results
were obtained by measuring the absorbance at 405 nm. Standard
curve was generated following the manufacturer’s instructions.
Bone histomorphometry
The mice were examined with an Inveon microCT (Siemen’s Inc.)
in vivo under mild anesthesia (2.5% isoflurane). The mice were
scanned with a large area CT camera that has a 30–40 micron high
resolution, low noise, 14-bit x-ray imaging detector with 409664096
pixels. (usable field of view for this configuration is 10 cm 610 cm).
The high performance 64-bit workstation controls the Inveon
multimodality scanners and was also used for reconstruction of
image data. The reconstructed microCT images were analyzed and
3D trabecular structural parameters were determined using the
Inveon Multimodality 3D Visualization software. The Bone volume/
Total volume (BV/TV), Bone surface area/Bone volume (BS/BV),
Trabecular Thickness (Tb.Th), Trabecular Space(Tb.Sp), Trabecu-
lar Number (Tb.N) and Trabecular Pattern Factor (Tb PF) were
analyzed from 4-wt and 4-mutant femurs (right and left femurs
combined) in 15-month old mice [63,64].
To elucidate osteoclastogenesis the bones were decalcified in
10% EDTA in PBS pH 7.4.The decalcified femurs were mounted
in the cryo-sectioning mounting media (Electron Microscopy
Sciences, Hatfield, PA) and stored at 280uC before sectioning.
The 5–6 mm sections were taken and fixed in 10% formalin with
PBS for 30 minutes, washed three times with PBS, blocked with
2% serum in PBS for 15 minutes. The bone sections were
immunostained with Tartrate Resistant Acid Phosphatase (TRAP)
antibody (Santa Cruz Biotechnology, Inc., Santa Cruz, CA)
overnight at 4uC. The sections were washed three times with PBS
and incubated with Fluorescein conjugated secondary antibody.
The sections were washed three times and mounted in DAPI
containing media. The fluorescence images were taken with Carl
Zeiss inverted fluorescence microscope.
Bone marrow derived macrophages (BMDMs) were prepared
from whole bone marrow of mice and cultured as follows. Bone
marrow (BM) cells from tibia and femur of 6- to 10-week-old mice
were flushed out with ice-cold a-MEM containing 10% heat-
inactivated FBS and penicillin/streptomycin. The cell suspension
was layered onto a Ficoll-Paque layer and centrifuged to buoyancy
separate the monocytes (GE Healthcare Bio-Sciences Corp., NJ).
This monocyte layer was washed and cultured with a-MEM and
10% FBS for 2–12 hr. The non-adherent cells were maintained
with RANKL (100 ng/mL) and M-CSF (50 ng/mL) for 3 days,
when new media was added to induce cells to undergo OC
differentiation.
Osteoclastogenesis cytokine sensitivity
The concentration of RANKL was progressively increased,
(12.5, 25, 50 and 100 ng/ml), but not M-CSF (2.5 ng/ml). The
level of the invariant cytokine is that used in our standard
osteoclastogenic assay is stated below. After 9 days, TRAP-
expressing multi-nucleated OCs was scored.
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